PAL perspective quote in Lab Soft News:

[Guest guest]

PAL perspective quoted in Lab Soft News:

Eligibility for Clinical Trials Based on Tumor Genotype

http://labsoftnews.typepad.com/lab_soft_news/2007/10/eligibility-for.html

" Let's turn this model around and think about an alternative approach. Tissue

from a patient's newly discovered tumor would be genotyped in a hospital lab or

reference lab and this information would then be submitted to a clearing house

with the identify of the patient protected. The patient's clinical and tumor

information would then be matched within this clearing house "

All the best,

~ Karl